RT Journal Article
SR Electronic
T1 Home-based pulmonary rehabilitation early after hospitalisation in COPD (early HomeBase): protocol for a randomised controlled trial
JF BMJ Open Respiratory Research
JO BMJ Open Resp Res
FD British Thoracic Society
SP e001107
DO 10.1136/bmjresp-2021-001107
VO 8
IS 1
A1 Narelle S Cox
A1 Aroub Lahham
A1 Christine F McDonald
A1 Ajay Mahal
A1 Paul O'Halloran
A1 Graham Hepworth
A1 Lissa Spencer
A1 Renae J McNamara
A1 Janet Bondarenko
A1 Heather Macdonald
A1 Samantha Gavin
A1 Angela T Burge
A1 Caitlin Le Maitre
A1 Cade Ringin
A1 Elizabeth Webb
A1 Amanda Nichols
A1 Ling-Ling Tsai
A1 Nia Luxton
A1 Stephanie van Hilten
A1 Mary Santos
A1 Hayley Crute
A1 Megan Byrne
A1 Helen Boursinos
A1 Jennifer Broe
A1 Monique Corbett
A1 Tunya Marceau
A1 Brooke Warrick
A1 Claire Boote
A1 Joanna Melinz
A1 Anne E Holland
YR 2021
UL http://bmjopenrespres.bmj.com/content/8/1/e001107.abstract
AB Introduction Chronic obstructive pulmonary disease (COPD) is characterised by exacerbations of respiratory disease, frequently requiring hospital admission. Pulmonary rehabilitation can reduce the likelihood of future hospitalisation, but programme uptake is poor. This study aims to compare hospital readmission rates, clinical outcomes and costs between people with COPD who undertake a home-based programme of pulmonary rehabilitation commenced early (within 2 weeks) of hospital discharge with usual care.Methods A multisite randomised controlled trial, powered for superiority, will be conducted in Australia. Eligible patients admitted to one of the participating sites for an exacerbation of COPD will be invited to participate. Participants will be randomised 1:1. Intervention group participants will undertake an 8-week programme of home-based pulmonary rehabilitation commencing within 2 weeks of hospital discharge. Control group participants will receive usual care and a weekly phone call for attention control. Outcomes will be measured by a blinded assessor at baseline, after the intervention (week 9–10 posthospital discharge), and at 12 months follow-up. The primary outcome is hospital readmission at 12 months follow-up.Ethics and dissemination Human Research Ethics approval for all sites provided by Alfred Health (Project 51216). Findings will be published in peer-reviewed journals, conferences and lay publications.Trial registration number ACTRN12619001122145.